5 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2026 | $55M | -$10M | 1.1% | -17.6% | -53.4% | -44.2% | — | — | $11M |
| 2025 | $33M | $4M | 2.8% | -6.1% | 22.3% | 18.0% | — | $2M | $9M |
| 2024 | $49M | $1M | 5.7% | 3.5% | 11.5% | 8.3% | -$802943 | $1M | $7M |
| 2023 | $28M | $969752 | 7.3% | 4.2% | 61.9% | 21.7% | -$917632 | $787860 | $1M |
| 2022 | $16M | $244587 | 4.0% | 1.7% | -16.7% | — | -$684059 | — | — |
How the market has priced HAO against its own fundamentals since 2024-01 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 4 years, Haoxi Health Technology Ltd's revenue has grown 35.7% per year. These are computed facts, not advice.
As of FY2026, Haoxi Health Technology Ltd reported — of total debt against $11M of cash; operating income covered interest expense -184.3×.
In FY2026, gross margin was 1.1%, operating margin -17.6%, and net margin -17.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.